Proposed LCD - MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules (DL39650)

National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER) Cancer Stat Facts: Thyroid Cancer. Accessed 6/26/2023.https://seer.cancer.gov/statfacts/html/thyro.htmlChen DW, Yeh MW. Disparities in thyroid care.Endocrinol Metab Clin North Am. 2022;51(2):229-241. doi:10.1016/j.ecl.2021.11.017Henley SJ, Ward EM, Scott S, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics.Cancer.2020;126(10):2225-2249. doi:10.1002/cncr.32802Lorusso L, Cappagli V, Valerio L, et al. Thyroid cancers: from surgery to current and future systemic therapies through their molecular identities.Int J Mol Sci. 2021;22(6):3117. doi:10.3390/ijms22063117Chernock RD, Hagemann IS. Molecular pathology of hereditary and sporadic medullary thyroid carcinomas.Am J Clin Pathol. 2015;143(6):768-777. doi:10.1309/AJCPHWACTTUYJ7DDMolinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.Nat Rev Endocrinol. 2017;13(11):644-660. doi:10.1038/nrendo.2017.76Davies L, Welch HG. Current thyroid cancer trends in the United States.JAMA Otolaryngol Head Neck Surg. 2014;140(4):317-322. doi:10.1001/jamaoto.2014.1Hoang JK, Nguyen XV, Davies L. Overdiagnosis of thyroid cancer: answers to five key questions.Acad Radiol. 2015;22(8):1024-1029. doi:10.1016/j.acra.2015.01.019Kitahara CM, Sosa JA. Understanding the ever-changing incidence of thyroid cancer.Nat Rev Endocrinol. 2020;16(11):617-618. doi:10.1038/s41574-020-00414-9Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013.JAMA. 2017;317(13):1338-1348. doi:10.1001/jama.2017.2719Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid cancer epidemic? The increasing impact of overdiagnosis.N Engl J Med. 2016;375(7):614-617. doi:10.1056/NEJMp1604412Lee M, Powers AE, Morris LGT, Marti JL. Reversal in thyroid cancer incidence trends in the United States, 2000-2017.Thyroid. 2020;30(8):1226-1227. doi:10.1089/thy.2020.0321Megwalu UC, Moon PK. Thyroid cancer incidence and mortality trends in the United States: 2000-2018.Thyroid. 2022;32(5):560-570. doi:10.1089/thy.2021.0662Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors.JAMA Oncol. 2016;2(8):1023-1029. doi:10.1001/jamaoncol.2016.0386Haugen BR, Sawka AM, Alexander EK, et al. American Thyroid Association guidelines on the management of thyroid nodules and differentiated Thyroid Cancer Task Force review and recommendation on the proposed renaming of encapsulated follicular variant papillary thyroid carcinoma without invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features.Thyroid. 2017;27(4):481-483. doi:10.1089/thy.2016.0628Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid ancer.Thyroid. 2016;26(1):1-133. doi:10.1089/thy.2015.0020Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): white paper of the ACR TI-RADS committee.J Am Coll Radiol. 2017;14(5):587-595. doi:10.1016/j.jacr.2017.01.046Kitahara CM, Pfeiffer RM, Sosa JA, Shiels MS. Impact of overweight and obesity on US papillary thyroid cancer incidence trends (1995-2015).J Natl Cancer Inst. 2020;112(8):810-817. doi:10.1093/jnci/djz202Ginzberg SP, Soegaard Ballester JM, Wirtalla CJ, et al. Insurance-based disparities in guideline-concordant thyroid cancer care in the era of de-escalation.J Surg Res. 2023;289:211-219. doi:10.1016/j.jss.2023.03.046Radhakrishnan A, Reyes-Gastelum D, Abrahamse P, et al. Physician specialties involved in thyroid cancer diagnosis and treatment: implications for improving health care disparities.J Clin Endocrinol Metab. 2022;107(3):e1096-e1105. doi:10.1210/clinem/dgab781Ginzberg SP, Soegaard Ballester JM, Wirtalla CJ, et al. Racial and ethnic disparities in appropriate thyroid cancer treatment, before and after the release of the 2015 American Thyroid Association Guidelines.Ann Surg Oncol. 2023;30(5):2928-2937. doi:10.1245/s10434-023-13158-3White C, Weinstein MC, Fingeret AL, et al. Is less more? A microsimulation model comparing cost-effectiveness of the revised American Thyroid Association's 2015 to 2009 Guidelines for the management of patients with thyroid nodules and differentiated thyroid Cancer.Ann Surg. 2020;271(4):765-773. doi:10.1097/SLA.0000000000003074Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology.Thyroid. 2017;27(11):1341-1346. doi:10.1089/thy.2017.0500Padmanabhan V, Marshall CB, Akdas Barkan G, et al. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the Bethesda system for reporting thyroid cytology when reviewing slides from different institutions: a study of interobserver variability among cytopathologists.Diagn Cytopathol. 2017;45(5):399-405. doi:10.1002/dc.23681Kuzan TY, Guzelbey B, Turan Guzel N, Kuzan BN, Cakir MS, Canbey C. Analysis of intra-observer and inter-observer variability of pathologists for non-benign thyroid fine needle aspiration cytology according to Bethesda System categories.Diagn Cytopathol. 2021;49(7):850-855. doi:10.1002/dc.24756Papaleontiou M, Hughes DT, Guo C, Banerjee M, Haymart MR. Population-based assessment of complications following surgery for thyroid cancer.J Clin Endocrinol Metab. 2017;102(7):2543-2551. doi:10.1210/jc.2017-00255National Comprehensive Cancer Network. Thyroid Carcinoma (Version 2.2023). Accessed 6/26/2023.https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdfAlexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.N Engl J Med. 23 2012;367(8):705-715. doi:10.1056/NEJMoa1203208Borowczyk M, Szczepanek-Parulska E, Olejarz M, et al. Evaluation of 167 gene expression classifier (GEC) and ThyroSeq v2 diagnostic accuracy in the preoperative assessment of indeterminate thyroid nodules: bivariate/HROC meta-analysis.Endocr Pathol. 2019;30(1):8-15. doi:10.1007/s12022-018-9560-5Silaghi CA, Lozovanu V, Georgescu CE, et al. Thyroseq v3, Afirma GSC, and microRNA panels versus previous molecular tests in the preoperative diagnosis of indeterminate thyroid nodules: a systematic review and meta-analysis.Front Endocrinol(Lausanne).2021;12:649522. doi:10.3389/fendo.2021.649522Vargas-Salas S, Martinez JR, Urra S, et al. Genetic testing for indeterminate thyroid cytology: review and meta-analysis.Endocr Relat Cancer.2018;25(3):R163-R177. doi:10.1530/ERC-17-0405Al-Qurayshi Z, Deniwar A, Thethi T, et al. Association of malignancy prevalence with test properties and performance of the gene expression classifier in indeterminate thyroid nodules.JAMA Otolaryngol Head Neck Surg. 2017;143(4):403-408. doi:10.1001/jamaoto.2016.3526Marti JL, Avadhani V, Donatelli LA, et al. Wide inter-institutional variation in performance of a molecular classifier for indeterminate thyroid Nodules.Ann Surg Oncol. 2015;22(12):3996-4001. doi:10.1245/s10434-015-4486-3Valderrabano P, Hallanger-Johnson JE, Thapa R, Wang X, McIver B. Comparison of postmarketing findings vs the initial clinical validation findings of a thyroid nodule gene expression classifier: a systematic review and meta-analysis.JAMA Otolaryngol Head Neck Surg. 2019;145(9):783-792. doi:10.1001/jamaoto.2019.1449Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples.J Clin Endocrinol Metab. 2011;96(11):3390-3397. doi:10.1210/jc.2011-1469Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.Cancer. 2014;120(23):3627-3634. doi:10.1002/cncr.29038Nikiforov YE, Carty SE, Chiosea SI, et al. Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance cytology.Thyroid. 2015;25(11):1217-1223. doi:10.1089/thy.2015.0305Marcadis AR, Valderrabano P, Ho AS, et al. Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules.Surgery. 2019;165(1):17-24. doi:10.1016/j.surg.2018.04.062Taye A, Gurciullo D, Miles BA, et al. Clinical performance of a next-generation sequencing assay (ThyroSeq v2) in the evaluation of indeterminate thyroid nodules.Surgery. 2018;163(1):97-103. doi:10.1016/j.surg.2017.07.032Valderrabano P, Khazai L, Leon ME, et al. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology.Endocr Relat Cancer. 2017;24(3):127-136. doi:10.1530/ERC-16-0512